Alexion Pharmaceuticals, a subsidiary of the drugmaker AstraZeneca, plans to acquire LogicBio Therapeutics, a gene therapy company.
AstraZeneca's offer price is $2.07 per share, the company said in an Oct. 3 news release, making the premium 660 percent and the total purchase price $68 million, according to the Boston Business Journal. Both boards of directors have approved the transaction, which is planned to finalize within four to six weeks.